Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Introduces New Prolyl Isomerase Screening Service

Published: Friday, February 01, 2013
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
Selcia Limited has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (“PPIases”).

The scope of service encompasses drug screening and functional assays, as well as profiling of compounds and determining specificity of inhibition against a representative panel of enzymes.

Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.  By combining its in-house expertise in screening services and medicinal chemistry, Selcia has already commenced delivery of clinical PPIase inhibitors to pharma clients.

The principal function of PPIases is to catalyse the cis-trans isomerisation of the X-Pro peptide bonds in polypeptide chains (where X is any amino acid). The isomerisation of peptide bonds to proline is more difficult than that of non-proline peptide bonds and is of physiological relevance in protein folding and in shape changes of fully folded proteins. This latter aspect represents an “on-off switch” of physiological properties of proteins.

Selcia has developed assays for members of all PPIase families and is constantly expanding the set of enzymes available for screening and profiling. Inhibitors of PPIases have important therapeutic potential in the area of infections (viruses, bacteria, yeast and moulds, and protozoa), inflammation, neuroprotection and cancer.

Simon Bury, Business Development Director – Discovery, comments: “PPIases are a large and unexploited family of drugable targets. They are not amenable to HTS and assays are difficult. Selcia is the only company offering this PPIase screening service and has the capability to take a PPIase target from hit finding to candidate stage. Selcia’s unique panel of PPIase screening assays was developed by our biology team to enable screening of compounds designed and synthesised by our medicinal chemists for several integrated drug discovery programs. We are delighted to be able to offer this panel of PPIases assays to researchers working in this area”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia and Cantab Announce Drug Discovery Collaboration
Partnership to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections.
Thursday, September 05, 2013
Selcia and NeuroVive to Develop New Mitochondrial Medicines
Selcia Limited and NeuroVive Pharmaceutical AB have signed a research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.
Monday, October 10, 2011
Selcia and ExonHit Therapeutics Announce Successful Fragment Screening Collaboration
Successful completion of a drug discovery project with ExonHit Therapeutics using Selcia’s fragment screening technology.
Thursday, April 21, 2011
Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board
Simon Saxby brings successful leadership and executive management experience to the role of Selcia’s CEO and Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board.
Thursday, February 24, 2011
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences Inc. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Tuesday, November 30, 2010
Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain
Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.
Thursday, November 25, 2010
Simon Saxby Joins Board at Selcia
Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Monday, June 28, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!